BPC August 24 update

Biotech stock events to watch for the remainder of 3Q 2019; Biotech week in Review

Weekly watchlist

The latest biotech trading week was dominated with Complete Response Letters (non-approval letters) issued by the FDA to two companies while another gave notice it also anticipates being on the receiving end by its PDUFA date in October.

We review these decisions and other price moving news in what was largely a week of negative news for the sector.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it was issued a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) of golodirsen injection for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. The CRL noted concerns regarding the risk of infections related to intravenous infusion ports and renal toxicity seen in preclinical trials. Shares closed the week down 25% to $93.61.

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) also announced that the FDA issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for Hetlioz (tasimelteon) for the treatment of Jet Lag Disorder (JLD). In the CRL, the FDA asserted that measures demonstrating improved sleep in its previous trials were unclear clinical significance.

Clearside Biomedical, Inc. (Nasdaq:CLSD) announced that it expects to receive a Complete Response Letter from the FDA for its New Drug Application (NDA) for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) by its PDUFA date of October 19, 2019. Clearside noted the FDA has requested stability data for its new manufacturing process, which it plans to provide with its resubmitted NDA in 1Q 2020. Shares closed the week down 40% to $0.71.

Endo International plc (NASDAQ: ENDP) announced that it has reached a settlement with Cuyahoga and Summit counties to pay $10m and will provide up to $1m of its Vasostrict and Adrenalin products free of charge. The settlement will avoid the company from going to trial, after being accused of contributing to the recent opioid epidemic. Shares closed the week up 28% to $2.90.

Retrophin, Inc. (NASDAQ: RTRX) shares closed the week down 27% to $13.07 following news its Phase 3 FORT trial evaluating fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN) did not meet its primary endpoint and did not demonstrate a difference between treatment groups.

Synlogic, Inc., (Nasdaq: SYBX) shares closed the week down 29% to $3.27 following news that it will discontinue development of SYNB1020, for the treatment of hyperammonemia. The decision follows interim analysis from its Phase 1b/2a trial which showed there was no evidence of blood ammonia lowering or changes in other endpoints relative to placebo.

Biotech stock events to watch for remainder of 3Q 2019:

Drug Stage Catalyst Market Cap

ADVM – Adverum Biotechnologies Inc.
Wet age-related macular degeneration (Wet-AMD)

Phase 1 Phase 1 data from first cohort presented September 12, 2019. Range change in BCVA -9.1 to +5.1 letters.
$401.6 million

AIMT – Aimmune Therapeutics Inc.
Peanut Allergy

PDUFA PDUFA date late-January 2020. Advisory Committee meeting September 13, 2019 voted in favor of supporting approval.
$1.4 billion

ALNY – Alnylam Pharmaceuticals Inc.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)

Phase 3 Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
$9.5 billion

ANAB – AnaptysBio Inc.
Generalized pustular psoriasis

Phase 2 Phase 2 data due mid-2019.
$1.1 billion

AVEO – AVEO Pharmaceuticals Inc.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer

Phase 3 Phase 3 interim data noted overall survival of 16.4 months vs 19.7 months for sorafenib.
$157.5 million

AZRX – AzurRx BioPharma Inc.
Cystic fibrosis

Phase 2 Phase 2 data due September 2019.
$27.1 million

ENTA – Enanta Pharmaceuticals Inc.
Non-alcoholic steatohepatitis (NASH)

Phase 2 Phase 2 initial data due 3Q 2019.
$1.4 billion

MRNS – Marinus Pharmaceuticals Inc.
Refractory status epilepticus (RSE)

Phase 2 Data due by the end of 3Q 2019.
$76.8 million

NERV – Minerva Neurosciences Inc
MIN-202 (seltorexant) vs quetiapine
Major Depressive Disorder

Phase 2 Phase 2 data due 3Q 2019.
$326.6 million

NTRP – Neurotrope Inc.
Alzheimer's disease

Phase 2 Phase 2 trial did not meet primary endpoint - September 9, 2019.
$13.4 million

SNGX – Soligenix Inc.
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer

Phase 3 Phase 3 interim analysis August 28, 2019 noted DMC recommended trial to continue with top-line data due 1H 2020.
$18.9 million

URGN – UroGen Pharma Ltd.
VesiGel UGN-102
Low grade non-muscle invasive bladder cancer (LG-NMIBC)

Phase 2b Phase 2b initial data due September 24, 2019.
$755.2 million

XERS – Xeris Pharmaceuticals Inc.
Glucagon Rescue Pen
Severe hypoglycemia

Approved FDA Approval announced September 10, 2019.
$286.1 million

ZEAL – Zealand Pharma A/S
Severe hypoglycemia in diabetes - children

Phase 3 Phase 3 data due September 2019.
$889.1 million